The UK Longitudinal Linkage Collaboration: A trusted research environment for the longitudinal research community

Objectives Our Trusted Research Environment (TRE) provides a centralised infrastructure to pool Longitudinal Population Studies’ (LPS) data and systematically link participants’ routine health, administrative and environmental records. All data are held in a centralised research resource which is now certified by UK Statistics Authority as meeting the Digital Economy Act standard. Approach We have created an unprecedented infrastructure integrating data from interdisciplinary and pan-UK LPS linked to participants’ NHS England records with delegated access responsibilities. Integrated and curated data are made available for pooled analysis within a functionally anonymous DEA and ISO 27001 accredited TRE. We developed a bespoke governance and data curation framework with LPS data managers and Public/participant contributors. New data pipelines are being built with partners at ADRUK and the Office of National Statistics to link non-health records. Our design supports long-term sustainability, linkage accuracy and the ability to link data at both an individual and household level. Results This organisation is a collaboration of >24 LPS with ~280,000 participants. Participants' data are linked to NHS records and geo-coded environmental exposures. This resource is now accessible for public benefit research for bona fide UK researchers. Administrative data including tax, work and pensions, and education are being added to the resource. This data flow is enabled by: (1) a model where TTP processes participant identifiers for many different data owners; (2) creation of a novel longitudinal data pipeline, enabling linkage, data extraction and update of records over time; (3) an access framework where Linked Data Access Panel considers applications on behalf of data owners (e.g., the NHS), with review by a Public Panel and distributing applications to LPS for approval of appropriate data use. Conclusion Our organisation provides a strategic research-ready platform for longitudinal research. We are extending linkages of LPS participants to previously inaccessible datasets. The research resource is positioned to allow researchers to investigate cross-cutting themes such as understanding health and social inequalities, health-social-environmental interactions, and managing the COVID-19 recovery

UK Longitudinal Linkage Collaboration – and the challenges in creating a new Longitudinal Populations Studies linked data resource.

Objectives The UK Longitudinal Linkage Collaboration (UK LLC) is a new, unprecedented infrastructure enabling research into the COVID-19 pandemic. The UK LLC integrates data from >20 UK longitudinal studies with systematically linked health, administrative and environmental records to facilitate cross-disciplinary COVID-19 research for accredited UK based researchers. Approach Bringing together all of the key components that form the UK LLC was a huge challenge that may have only been possible in the midst of the pandemic. First, we collaborated with the Longitudinal Population Studies (LPS) to create and agree how data linkage, data provision and applications to access the UK LLC would work. In parallel, public contributors helped to create fair processing materials. Finally, we worked closely with NHS Digital and other key national data providers to organise approvals for all studies to be linked, and for the UK LLC to have delegated decision-making for research applications. Results We faced a myriad of challenges creating the UK LLC including: • Short timeframe and short-term funding structure – initial funding for six months with an 18-month extension. • Working across >20 different LPS and four nations with different structures for access, consent and data provision. • Lack of capacity at various points in the data pipeline due to the volume of COVID-19 research required and underway across the involved organisations. • Data processing complexities – split data method means no one can see the entire process therefore catching linkage errors requires working across four different organisations. • With such complex data flows it is challenging to find the balance with communications about data to the public – being accurate about what we are doing, but expressing the complexity in lay terms. Conclusion Creating the UK LLC required collaboration with LPS, data providers and researchers. An iterative approach to creating the data application and data provision pipelines was crucial in developing these processes. The UK LLC was built quickly, from initial funding in October 2020 to provisioning data to researchers in December 2021

Ethnic differences in the indirect effects of the COVID-19 pandemic on clinical monitoring and hospitalisations for non-COVID conditions in England: a population-based, observational cohort study using the OpenSAFELY platform

Background: The COVID-19 pandemic disrupted healthcare and may have impacted ethnic inequalities in healthcare. We aimed to describe the impact of pandemic-related disruption on ethnic differences in clinical monitoring and hospital admissions for non-COVID conditions in England. Methods: In this population-based, observational cohort study we used primary care electronic health record data with linkage to hospital episode statistics data and mortality data within OpenSAFELY, a data analytics platform created, with approval of NHS England, to address urgent COVID-19 research questions. We included adults aged 18 years and over registered with a TPP practice between March 1, 2018, and April 30, 2022. We excluded those with missing age, sex, geographic region, or Index of Multiple Deprivation. We grouped ethnicity (exposure), into five categories: White, Asian, Black, Other, and Mixed. We used interrupted time-series regression to estimate ethnic differences in clinical monitoring frequency (blood pressure and Hba1c measurements, chronic obstructive pulmonary disease and asthma annual reviews) before and after March 23, 2020. We used multivariable Cox regression to quantify ethnic differences in hospitalisations related to diabetes, cardiovascular disease, respiratory disease, and mental health before and after March 23, 2020. Findings: Of 33,510,937 registered with a GP as of 1st January 2020, 19,064,019 were adults, alive and registered for at least 3 months, 3,010,751 met the exclusion criteria and 1,122,912 were missing ethnicity. This resulted in 14,930,356 adults with known ethnicity (92% of sample): 86.6% were White, 7.3% Asian, 2.6% Black, 1.4% Mixed ethnicity, and 2.2% Other ethnicities. Clinical monitoring did not return to pre-pandemic levels for any ethnic group. Ethnic differences were apparent pre-pandemic, except for diabetes monitoring, and remained unchanged, except for blood pressure monitoring in those with mental health conditions where differences narrowed during the pandemic. For those of Black ethnicity, there were seven additional admissions for diabetic ketoacidosis per month during the pandemic, and relative ethnic differences narrowed during the pandemic compared to the White ethnic group (Pre-pandemic hazard ratio (HR): 0.50, 95% confidence interval (CI) 0.41, 0.60, Pandemic HR: 0.75, 95% CI: 0.65, 0.87). There was increased admissions for heart failure during the pandemic for all ethnic groups, though highest in those of White ethnicity (heart failure risk difference: 5.4). Relatively, ethnic differences narrowed for heart failure admission in those of Asian (Pre-pandemic HR 1.56, 95% CI 1.49, 1.64, Pandemic HR 1.24, 95% CI 1.19, 1.29) and Black ethnicity (Pre-pandemic HR 1.41, 95% CI: 1.30, 1.53, Pandemic HR: 1.16, 95% CI 1.09, 1.25) compared with White ethnicity. For other outcomes the pandemic had minimal impact on ethnic differences. Interpretation: Our study suggests that ethnic differences in clinical monitoring and hospitalisations remained largely unchanged during the pandemic for most conditions. Key exceptions were hospitalisations for diabetic ketoacidosis and heart failure, which warrant further investigation to understand the causes

The philanthropist next door

University campuses are peppered with buildings named for big benefactors, the people whose sizable gifts have helped propel higher education forward, often in tough economic times. But behind every major donor is a throng of everyday donors - alumni and community members, employees and retirees, families and clubs - whose contributions fuel our progress.Story by Mizzou Staff ; illustrations by Jacqui Oakley

Efficacy of LY303366 against Amphotericin B-Susceptible and -Resistant Aspergillus fumigatus in a Murine Model of Invasive Aspergillosis

LY303366 is a novel antifungal echinocandin with excellent in vitro activity against Aspergillus spp. We compared four doses (1, 2.5, 10, and 25 mg/kg of body weight) of LY303366 with amphotericin B (0.5 to 5 mg/kg) in a temporarily neutropenic murine model of invasive aspergillosis against an amphotericin B-susceptible (AF210) and an amphotericin B-resistant (AF65) Aspergillus fumigatus isolate based on in vivo response. Mice were immunosuppressed with cyclophosphamide (200 mg/kg) and infected 3 days later. Treatment started 18 h after infection and lasted for 10 days. LY303366 was given once daily intravenously for 10 days, and amphotericin B (at 0.5, 2, and 5 mg/kg) was given once daily intraperitoneally for 10 days, or only on days 1, 2, 4, and 7 (at 5 mg/kg). Kidneys and lungs from survivors were cultured on day 11. Control mice in both experiments had 90 to 100% mortality. Amphotericin B at 0.5 mg/kg and LY303366 at 1 mg/kg yielded 10 to 20% survival rates for mice infected with either AF210 or AF65. Amphotericin B at 2 and 5 (both regimens) mg/kg yielded a 70 to 100% survival rate for mice infected with AF210 but a 10 to 30% survival rate for mice infected with AF65 (P = 0.01 to 0.04 compared with AF210). Against AF210 and AF65, LY303366 at 2.5, 10, and 25 mg/kg produced a survival rate of 70 to 80%, which was as effective as amphotericin B for AF210, but superior to amphotericin B for AF65 (P < 0.03 to 0.0006). For AF65, LY303366 at 10 and 25 mg/kg/day was superior to amphotericin B at 2 and 5 mg/kg/day in reducing tissue colony counts (P = 0.01 to 0.003), and for AF210, amphotericin B at 5 mg/kg/day and at 5 mg/kg in four doses was more effective than all four regimens of LY303366 in reducing renal culture counts (P = 0.01 to 0.0001). The present study shows, for the first time, that in vivo resistance of A. fumigatus to amphotericin B exists, although this could not be detected by in vitro susceptibility assays. Furthermore, LY303366 appears to be effective against amphotericin B-susceptible and -resistant A. fumigatus infection in this model and should be further evaluated clinically

Building capacity for climate adaptation planning in protected area management: Options and challenges for World Heritage

"Response and adaptation to the impacts of climate change is a vital and increasing requirement for protected area management. On the ground managers of cultural and natural values in protected places have requested practical guidance on how to undertake climate change impact analysis, vulnerability assessment, and adaptation plan- ning together with enhanced capacity for planning with partners, rightsholders and stakeholders. In this paper we explore how co-development and subsequent testing among World Heritage site managers, Indigenous ex- perts and researchers, produced guidance for assessing, responding to and planning for the impacts of climate change on the diverse values of World Heritage sites in Australia. We draw on the diversity of cultural and natural heritage values associated with the terrestrial, coastal and marine environments in Australian World Heritage sites, and the broad range of institutional contexts in these sites, to highlight considerations of relevance to other protected areas (including other World Heritage sites around the world, Ramsar wetlands and marine protected areas). Our paper highlights that, for climate adaptation planning to become a normal part of man- agement, there is a need for ongoing capacity building, including around the use of climate information to inform adaptation planning and implementation, as well as integrating Indigenous perspectives. Building capacity mayinvolve trial and error, negotiation, sharing, sourcing and interpreting new information, and changes in""expectations. It will require novel and more dynamic relationships between partners and stakeholders. Managers should include capacity building for climate adaptation planning and implementation as a specific climate"adaptation task in their planning.

Stratified analyses refine association between TLR7 rare variants and severe COVID-19

Summary: Despite extensive global research into genetic predisposition for severe COVID-19, knowledge on the role of rare host genetic variants and their relation to other risk factors remains limited. Here, 52 genes with prior etiological evidence were sequenced in 1,772 severe COVID-19 cases and 5,347 population-based controls from Spain/Italy. Rare deleterious TLR7 variants were present in 2.4% of young (<60 years) cases with no reported clinical risk factors (n = 378), compared to 0.24% of controls (odds ratio [OR] = 12.3, p = 1.27 × 10−10). Incorporation of the results of either functional assays or protein modeling led to a pronounced increase in effect size (ORmax = 46.5, p = 1.74 × 10−15). Association signals for the X-chromosomal gene TLR7 were also detected in the female-only subgroup, suggesting the existence of additional mechanisms beyond X-linked recessive inheritance in males. Additionally, supporting evidence was generated for a contribution to severe COVID-19 of the previously implicated genes IFNAR2, IFIH1, and TBK1. Our results refine the genetic contribution of rare TLR7 variants to severe COVID-19 and strengthen evidence for the etiological relevance of genes in the interferon signaling pathway